FDA OKs Alpelisib, First PI3K Inhibitor for Breast Cancer

The FDA approved alpelisib (Piqray, Novartis) to be used with the FDA-approved fulvestrant in certain patients with breast cancer. A companion test was also approved.
FDA Approvals …read more